Effect of Vitamine D3 for the patients whith chronic hepatitis C who recieved PEG-interferon alpha plus ribavirin: possible applicaition for database establishment.

Effect of Vitamine D3 for the patients whith chronic hepatitis C who recieved PEG-interferon alpha plus ribavirin: possible applicaition for database establishment. - EVIDENCE study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003694

Enrollment

Registered

2010-06-10

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

Vitamine D3, PEG-interferon alpha and ribavirin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic hepatits C complicating with osteoporosis.

Exclusion criteria

Exclusion criteria: Any contraindication for (PEG) interferon, ribavirin, and Vitamine D3 suppliments.

Design outcomes

Primary

Measure	Time frame
Sustained viral response (SVR)	—

Countries

Japan

Contacts

Public ContactYoshiyuki Ueno

Tohoku Univerisity Graduate School of Medicine Div. Gastroenterology

yoshiyuueno-gi@umin.ac.jp022-717-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026